29395results about "Antivirals" patented technology

Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.

Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) or formula (II) and methods for preparing the stabilizing agents and the lipid nanoparticle are provided.

The technology described herein is directed to spray-dried biotherapeutic matrix compositions comprising a bacterial preparation, which is formulated for administration by inhalation. Also described herein unit dosage forms of such spray-dried biotherapeutic matrix compositions, devices comprising such pharmaceutical compositions, methods of producing such pharmaceutical compositions, and methods of treating diseases, such as bronchopulmonary diseases, among others, using such spray-dried biotherapeutic matrix compositions.

The disclosure provides a method for systemic delivery of a therapeutically effective amount of epinephrine to a subject comprising orally administering dipivefrin or a dipivefrin salt to the subject. The disclosure also includes a method of treatment of a disease amenable to treatment by in vivo delivery of systemic epinephrine comprising administering dipivefrin or a dipivefrin salt to a subject in need of in vivo delivery of systemic epinephrine. The disease can be a respiratory disorder, anaphylaxis, cancer, or a microbial infection. The disclosure also includes dipivefrin or dipivefrin HCl orally dissolving tablets.

The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.

The invention belongs to the technical field of microbial fermentation, and particularly relates to a plant lactobacillus XD117, application of the plant lactobacillus XD117 in fermentation of astragalus membranaceus, an astragalus membranaceus fermentation product and a preparation method of the astragalus membranaceus fermentation product. The bacterial strain is lactobacillus plantarum XD117 and is preserved in the China Center for Type Culture Collection, and the preservation number of the bacterial strain is CCTCC NO: M 20241730. The preparation method of the astragalus mongholicus fermentation product comprises the following steps: inoculating the lactobacillus plantarum XD117 into astragalus mongholicus enzymatic hydrolysate, and fermenting in a fermentation temperature range suitable for the lactobacillus plantarum XD117 to obtain the astragalus mongholicus fermentation product. The total content of calycosin, formononetin, calycosin glucoside and formononin in the astragalus mongholicus fermentation product is high, and the astragalus mongholicus fermentation product has a very good antioxidant effect.

To provide antibodies that bind to lymphocyte activation gene 3 (LAG3) protein, which is a T cell co-inhibitor, and methods of use.SOLUTION: In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing means of treating a disease or disorder such as cancer or viral infection. The antibodies of the present invention are useful, inter alia, for targeting immune cells expressing LAG3 and for modulating LAG3 activity.SELECTED DRAWING: None

The invention discloses a recombinant herpes zoster vaccine as well as a preparation method and application thereof, and particularly relates to the technical field of biological medicines. The recombinant herpes zoster vaccine comprises a recombinant herpes zoster vaccine fusion protein purified product HN101 and a liposome mixture HA201, and the recombinant herpes zoster fusion protein gE-gD is constructed by recombining reconstructed gE protein and reconstructed gD protein. The gE-gD recombinant herpes zoster fusion protein is obtained by reconstructing gE protein of varicella-herpes zoster virus and gD protein of HSV through a gene recombination technology and then recombining the gE protein and the gD protein. After the gE-gD recombinant herpes zoster fusion protein is combined with a liposome mixture HA201, stronger immune response can be induced, the antibody titer and cellular immunity are improved, the vaccine effect is enhanced, and meanwhile, the potential infection risk is avoided.

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The invention provides methods and means for the inhibition or neutralisation of death receptor / death ligand members of the tumour necrosis factor superfamil and TNF receptor superfamilies and / or the Toll-like receptor family, and / or NOD-like receptor and / or of the signalling induced via these receptors, preferably in combination with each other and / or with anti-inflammatory agents, in treating diseases such as Acute Respiratory Distress Syndrome (ARDS), such as that caused by airway-targeting viruses, such as SARS coronaviruses.

The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. Specific embodiments relate to RNA betacoronavirus vaccines formulated in a lipid nanoparticle.

The invention belongs to the technical field of biology, and provides a porcine epidemic diarrhea virus mRNA vaccine and application. The mRNA molecule comprises a coding region for coding the S protein of the PEDV; the PEDV is of a G2a type, and two proline mutations I1076P and L1077P are introduced into an S protein. The invention further discloses a DNA molecule. An S protein of PEDV; a recombinant plasmid; recombining the host cell; an mRNA vaccine formulation which can be used to prepare an antibody against the S protein of PEDV after immunizing an animal; the invention further discloses application of the mRNA molecule, the DNA molecule, the recombinant plasmid or the host cell to preparation of a medicine for preventing PEDV (Porcine Epidemic Diarrhea Virus) infection. The vaccine prepared by the invention is fast in antibody generation and high in protection rate, can generate high-level neutralizing antibodies in serum and breast milk of sows after the pregnant sows are immunized before parturition, has a remarkable protection effect on piglets, and can effectively prevent the piglets from being infected with PEDV (Porcine Epidemic Diarrhea Virus).

A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine.

The invention belongs to the field of biological medicines, and particularly relates to a varicella-zoster virus gE fusion protein as well as a preparation method and application thereof. The varicella-zoster virus gE fusion protein comprises an amino acid sequence as shown in SEQ ID NO: 1 and at least one of the following fragments: a signal peptide, a Foldon sequence, a Ferritin sequence and a His tag sequence, the signal peptide can improve the protein expression quantity, the Foldon sequence can improve the stability of the protein, the particle size of an antigen can be increased, the immunogenicity of the antigen can be improved, and the fusion protein can be used for preparing a medicine for treating the varicella-zoster virus gE fusion protein. The Ferritin sequence can enhance immune response, a vaccine prepared from the gE fusion protein has excellent immunogenicity, and compared with a commercially available vaccine Shingrix, higher humoral immunity and cellular immunity levels can be induced.

The invention provides an artificial nucleic acid molecule which is used for improving the expression quantity of target amino acid, polypeptide or protein. The artificial nucleic acid molecule at least comprises a target 5'untranslated region (UTR), a target coding region (CDS) and a target 3 'untranslated region (UTR). Wherein the sequence of the target 5 'UTR is one of the following sequences: 5' UTR of a high-expression gene and a 5 'UTR variant of the high-expression gene. The sequence of the target 3 'UTR is one of the following sequences: 3' UTR of a high-expression gene and a 3 'UTR variant of the high-expression gene. Optionally, the artificial nucleic acid molecule may further comprise, for example, a 5 '-end cap structure (Cap), a PolyA tail. The 5 'UTR and the 3' UTR have regulating effects on translation and stability of nucleic acid molecules, so that the 5 'UTR, the 3' UTR and variants thereof are selected from high-expression genes, the nucleic acid molecules can be further stabilized and are not easy to degrade, and the amount of protein or polypeptide obtained by translation of the nucleic acid molecules can be increased. The invention also provides methods for making, delivering, and using such artificial nucleic acid molecules, as well as the use of the artificial nucleic acid molecules for the treatment and / or prevention of related diseases or disorders.

The invention discloses an anti-pestivirus broad-spectrum neutralizing monoclonal antibody and application thereof, and belongs to the field of immune globulin. The anti-pestivirus monoclonal antibody or the antigen binding fragment thereof comprises a heavy chain variable region (SEQ ID No.1) and a light chain variable region (SEQ ID No.3). The monoclonal antibody provided by the invention can identify hog cholera virus and all known plague virus members (BVDV1, BVDV2, BDV, HoBiPeV, AydinPeV and OVPV) capable of infecting cattle and sheep at present, has good neutralizing ability, and can be prepared into a diagnostic product for plague virus antigen-antibody detection. The monoclonal antibody and a diagnostic product developed based on the monoclonal antibody can be used for serological diagnosis and immune effect evaluation of pestivirus, pestivirus pathogen detection of experimental serum products and the like, and have wide application prospects in the fields of clinical diagnosis and the like.

The invention provides an UTR (Untranslated Region) element H2202 P1-G as well as a construction method and application thereof, and relates to the technical field of mRNA (messenger ribonucleic acid). According to the present invention, the ribosome load prediction and the secondary structure optimization are performed on the natural 5 'UTR of the HIV TAT 202 gene through the BaidleHelix platform, and the obtained HTAT 202 P1 sequence avoids the inhibitory hairpin structure so as to significantly improve the luciferase expression quantity compared to the natural UTR; an ncRNA sequence without a secondary structure is introduced on the basis of the HTAT 202 P1, translation inhibition of a 5 'cap region is further relieved, and the protein expression quantity of the constructed H2202 P1-G mutant (the DNA sequence of the H2202 P1-G is as shown in SEQ NO 1, and the RNA sequence is as shown in SEQ NO 2) is further improved.

The invention relates to the field of cubilose peptides, in particular to preparation and application of cubilose glycopeptides capable of preventing and assisting in treating gynecological inflammation and gastrointestinal inflammation. The invention provides cubilose glycopeptide which comprises cubilose peptide, sialylated O-glycan and sialylated N-glycan, and the cubilose peptide is connected with the sialylated O-glycan and / or the sialylated N-glycan. The cubilose glycopeptide provided by the invention has unique sialylated O-glycans and N-glycans, has unique biological activity and functions and synergistic effect compared with the cubilose glycopeptide without N-glycans or O-glycans and non-sialylated cubilose peptides, and forms and enhances the inhibition effect on pathogens and the antiviral effect; therefore, the compound has unique advantages in the aspect of preventing and treating related problems. The sialic acid binding type cubilose glycopeptide has stronger antibacterial activity, especially has an inhibition effect on pathogens such as candida albicans and helicobacter pylori, and also has an antiviral effect.

The present disclosure provides crystalline forms, solvates and hydrates of (R)-5-fluoro-2-methyl-1-((R)-5-(pyridin-2-yl)-2,3-dihy dro-lH-indene-2-carbonyl)indoline-6- sulfonamide, and methods of making.

Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Notably, CAR constructs with an intracellular domain of FcεRIγ had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK / NK-92 cells.

Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

The invention discloses a bovine I-type alpha interferon-ferritin fusion protein, a mutant thereof, a preparation method and an application of the bovine I-type alpha interferon-ferritin fusion protein. The bovine I-type alpha interferon is fused with a ferritin subunit, and interferon molecules are highly repeatedly and orderly displayed on the surface of a ferritin nanocage by utilizing the self-assembly characteristic of ferritin, so that the expression level, the structural stability and the antiviral activity of the interferon are remarkably improved. The fusion protein is further subjected to single-site or multi-site rational design mutation, and a mutant with significantly improved antiviral activity and stability is obtained. According to the invention, a silkworm or insect cell eukaryotic expression system is adopted to express the fusion protein or the mutant thereof, and the expression system is safe to operate, simple and convenient in procedure, low in cost and extremely beneficial to large-scale industrial production; the prepared fusion protein or mutant nanoparticles have application prospects in preparation of drugs or reagents for preventing or treating bovine viral diseases.

The invention provides a porcine epidemic diarrhea virus S protein mutant, a nucleic acid molecule, a subunit vaccine and application. Compared with wild type porcine epidemic diarrhea virus S protein, the porcine epidemic diarrhea virus S protein mutant has the advantage that amino acid at the 1076th site, amino acid at the 1077th site, amino acid at the 1016th site and amino acid at the 1017th site are mutated into proline. The natural trimer which is stable and maintains the conformation of the S protein before fusion is constructed, the safe and efficient PEDV subunit vaccine is obtained, and the use effect and immunogenicity of the porcine epidemic diarrhea vaccine can be improved; moreover, compared with a wild type S protein, the porcine epidemic diarrhea virus S protein mutant disclosed by the invention has a higher expression quantity.

The invention belongs to the field of interferon gene engineering, and discloses a long-acting cat omega2 interferon recombinant protein FeIFN-omega2-Fc and application, and the FeIFN-omega2-Fc provided by the invention has the characteristics of high activity, obvious antiviral effect and long half-life period. The applicant carries out effective fusion and mutation on the basis of omega2 interferon, and finally obtains the recombinant protein FeIFN-omega2-Fc. The protein obviously activates downstream signal factors of interferon, has the effect of resisting various cat viruses, shows good safety and curative effect when cat herpes treatment experiments are carried out on cats, and compared with FeIFN-omega2, the half-life period of recombinant interferon is obviously prolonged. The FeIFN-omega2-Fc has a good antiviral effect, can effectively prevent and treat cat viral diseases, has a wide application prospect, and particularly has a relatively good popularization potential in clinical treatment.

The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or prophylaxis of an infection with Norovirus or a disorder related to such an infection. In particular, the present invention concerns a Norovirus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.